Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | CTSV | O60911 | 2/20 | 0.44 |
| ▸ | CTSL | P07711 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.40 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.40 |
| ▸ | ANO2 | Q9NQ90 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3765923 | 0.89 | POLB (0.48) | POLBALDH1A1MAPTLMNAMEN1 | |
| SCHEMBL10955131 | 0.84 | POLB (0.49) | POLBALDH1A1CTSVCTSLMAPT | |
| SCHEMBL2647221 | 0.82 | AKR1C3 (0.47) | POLBALDH1A1CTSVCTSLMAPT | |
| SCHEMBL7653556 | 0.82 | RAB9A (0.49) | POLBCTSVCTSLMAPTLMNA | |
| SCHEMBL5937228 | 0.80 | CYP46A1 (0.43) | ALDH1A1MAPTLMNAHPGDL3MBTL1 | |
| SCHEMBL4634707 | 0.80 | EPAS1 (0.47) | ALDH1A1LMNAHPGDL3MBTL1MAPK1 | |
| SCHEMBL2314446 | 0.80 | NOTUM (0.47) | ALDH1A1MAPTHPGDL3MBTL1KMT2A | |
| SCHEMBL5578046 | 0.80 | HTT (0.53) | POLBALDH1A1MAPTLMNAHPGD | |
| SCHEMBL9234021 | 0.80 | ALDH1A1 (0.52) | POLBALDH1A1CTSVCTSLMAPT | |
| SCHEMBL570064 | 0.80 | TDP1 (0.57) | POLBALDH1A1CTSVCTSLMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6673930-B2 | PREPARING A SELECTIVE GLUCOCORTICOID RECEPTOR AGENTS BY CYCLIZATION, DEHALOGENATION, AMINATION, ETHERIFICATION, HYDROXYLATION | ABBVIE INC. | 2004-01-06 | — | — | US | claimed |
| US-20030069427-A1 | Process for the preparation of 5-(substituted)-10 methoxy-2,2,4-trimethyl-2,5-dihydro- 1H-chromeno [3,4-f] quinolines and derivatives thereof | ABBVIE INC. | 2003-04-10 | — | — | US | claimed |
| WO-2003027117-A1 | A PROCESS FOR THE PREPARATION OF 5-(SUBSTITUTED)-10-METHOXY-2,2,4-TRIMETHYL-2,5-DIHYDRO-1H-CHROMENO[3,4-F]QUINOLINES AND DERIVATIVES THEREOF | ABBOTT LABORATORIES (US) | 2003-04-03 | — | — | WO | claimed |
| US-6518430-B1 | The present invention relates to an efficient process for the preparation of 5-(substituted)-10-methoxy-2,2,4-trimethyl-2,5- dihydro-1H-chromeno(3,4-f)quinolines. | ABBOTT LABORATORIES | 2003-02-11 | — | — | US | claimed |
| US-20040157866-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-12 | — | — | US | disclosed |
| EP-1383760-A1 | BIARYLCARBOXAMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-28 | — | — | EP | disclosed |
| US-6673930-B2 | PREPARING A SELECTIVE GLUCOCORTICOID RECEPTOR AGENTS BY CYCLIZATION, DEHALOGENATION, AMINATION, ETHERIFICATION, HYDROXYLATION | ABBVIE INC. | 2004-01-06 | — | — | US | disclosed |
| US-20030069427-A1 | Process for the preparation of 5-(substituted)-10 methoxy-2,2,4-trimethyl-2,5-dihydro- 1H-chromeno [3,4-f] quinolines and derivatives thereof | ABBVIE INC. | 2003-04-10 | — | — | US | disclosed |
| WO-2003027117-A1 | A PROCESS FOR THE PREPARATION OF 5-(SUBSTITUTED)-10-METHOXY-2,2,4-TRIMETHYL-2,5-DIHYDRO-1H-CHROMENO[3,4-F]QUINOLINES AND DERIVATIVES THEREOF | ABBOTT LABORATORIES (US) | 2003-04-03 | — | — | WO | disclosed |
| US-6518430-B1 | The present invention relates to an efficient process for the preparation of 5-(substituted)-10-methoxy-2,2,4-trimethyl-2,5- dihydro-1H-chromeno(3,4-f)quinolines. | ABBOTT LABORATORIES | 2003-02-11 | — | — | US | disclosed |
| WO-2002090347-A1 | AMIDE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069427-A1 | Process for the preparation of 5-(substituted)-10 methoxy-2,2,4-trimethyl-2,5-dihydro- 1H-chromeno [3,4-f] quinolines and derivatives thereof | HTR3C, CYP3A5, NQO2 | POLB 2227/4885ALDH1A1 1684/4885CTSV 2880/4885 |
| US-20040157866-A1 | Amide compounds | APOB, NR1H2, NR1H3 | POLB 1962/4885ALDH1A1 2901/4885CTSV 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.